I took a glance at all four abstracts. Nothing too exciting or new in the meta-analysis abstract or the ex-vivo treatment of monocytes abstract. Interesting observation in the BETonMACE post-hoc analysis about diabetic patients on insulin having greater cardio risk and responding better to apabetalone. In part, could be because these patients were more likely to be on the SGLT2i and GLP1-R agonists. The COVID-19 abstract is impressive with the findings of dramatically reduced ACE2 expression in kidney and liver cells treated with apabetalone. There seems to be a BRD4 enhancer element in the promoter of ACE2, such that apabetalone binding disruption this transcriptional enhancer effect. Cool stuff.

BDAZ